ISRCTN09968140已完成未知
A multi-centre open-label randomised controlled trial measuring the efficacy of tranexamic acid to reduce post partum haemorrhage volume
niversity Hospital Research Delegation of Lille (France)0 个研究点目标入组 144 人开始时间: 2011年3月24日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 144
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Female
入选标准
- •Patients were included in the study when PPH was more than 800 mL
排除标准
- •1. Age < 18 years
- •2. Asence of informed consent
- •3. Caesarean section
- •4. Presence of known haemostatic abnormalities before pregnancy
- •5. History of previous thrombosis or epilepsy
研究者
相似试验
尚未招募
Unknown
A multi-center open-label randomized controlled trial to evaluate the efficacy of the Mantis Clip for defect closure following colorectal endoscopic submucosal dissectioJPRN-UMIN000054070The Jikei University School of Medicine250
进行中（未招募）
不适用
A controlled randomized open-label multicentre study evaluating if early initiation of everolimus (Certican®) and early elimination of cyclosporine (Sandimmun Neoral®) in de novo heart transplant recipients can improve long-term renal function and slow down the progression of chronic allograft vasculopathy. - SCHEDULEHeart transplantationMedDRA version: 14.1Level: PTClassification code 10019314Term: Heart transplantSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2009-013074-41-DKovartis Healthcare A/S100
进行中（未招募）
1 期
A controlled randomized open-label multicentre study evaluating if early initiation of everolimus (Certican®)and early elimination of cyclosporine (Sandimmun Neoral®) in de novo heart transplant recipients can improve long-term renal function and slow down the progression of chronic allograft vasculopathy. - ScheduleHeart transplantationMedDRA version: 12.1Level: LLTClassification code 10019314Term: Heart transplantEUCTR2009-013074-41-NOovartis Norge AS
进行中（未招募）
不适用
A controlled randomized open-label multicentre study evaluating if early initiation of everolimus (Certican®)and early elimination of cyclosporine (Sandimmun Neoral®) in de novo heart transplant recipients can improve long-term renal function and slow down the progression of chronic allograft vasculopathy. - ScheduleEUCTR2009-013074-41-SEovartis Norge AS100
进行中（未招募）
不适用
A controlled randomized open-label multicentre study evaluatiing if early conversion to everolimus (Certican) from cyclosporine (Neoral) in de novo renal transplant receipients can improve long-term renal function and slow down the progression of chronic allograft nephropathy - CENTRAEUCTR2007-000771-42-SEovartis Pharma Services250